Dr. Shapiro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UCLA Medical Center
200 Medical Plaza, Suite 365
Los Angeles, CA 90095Phone+1 310-825-8061Fax+1 310-825-8061
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1978 - 1981
- Albert Einstein College of MedicineClass of 1978
Certifications & Licensure
- CA State Medical License 1979 - 2025
- NY State Medical License 2015 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2006 May 01
- Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension Start of enrollment: 2008 Jul 01
- Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Start of enrollment: 2009 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 711 citationsContinuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.David B. Badesch, Victor F. Tapson, Michael D. McGoon, Bruce H. Brundage, Lewis J. Rubin
Annals of Internal Medicine. 2000-03-21 - 713 citationsTadalafil Therapy for Pulmonary Arterial HypertensionNazzareno Galiè, Bruce H. Brundage, Hossein Ardeschir Ghofrani, Ronald J. Oudiz, Gérald Simonneau
Circulation. 2009-06-09 - 276 citationsImatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established TherapyHossein Ardeschir Ghofrani, Nicholas W. Morrell, Marius M. Hoeper, Horst Olschewski, Andrew J. Peacock
American Journal of Respiratory and Critical Care Medicine. 2010-11-01
Press Mentions
- United Therapeutics Announces FDA Approval of Tyvaso DPI™May 24th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: